Ju Hai Heng Chuang Secures RMB 30 Million in Series Angel Funding to Advance Nucleic Acid Synthesis Excellence

VCBeat recently learned that Hangzhou Juhai Hengchuang Technology Co., Ltd.Company(hereinafter referred to as“Juhai Hengchuang”) CompletedRMB 30 million in angel round financing. This round of financing was led byHangzhouTigerYeah CapitalLead Investor,Deshi CapitalCo-investment,Yiran CapitalServing as the exclusive financial advisor. The company has recently officially launched its Series A financing round and looks forward to mutual cooperation with friends in the industry and investment community.

Hangzhou Juhai Hengchuang Technology Co., Ltd. has three wholly-owned subsidiaries: Beijing Haijing Gaochuang, Qingdao Judianer Technology Co., Ltd., and Hunan Hengyi Technology. Each subsidiary is responsible for distinct yet complementary business operations. As a leading platform company in the upstream sector of nucleic acid synthesis, the company serves four major customer categories downstream: nucleic acid therapeutics, diagnostics, service providers, and scientific research. Despite a relatively sluggish market environment, the company has achieved rapid performance growth and successful international expansion, striving to quickly surpass the RMB 100 million revenue milestone.

Beijing Haijing Gaochuang, established in 2017, is recognized as both a Beijing High-Tech Enterprise and a Zhongguancun High-Tech Enterprise. The company is primarily engaged in the design and manufacturing of equipment products. Its flagship offerings include core equipment such as nucleic acid synthesis systems, ammonolysis elution devices, and workstations of various specifications. The company’s integrated fully automated production lines hold a significant position in the nucleic acid synthesis industry. Backed by a mature R&D team with strong capabilities in research, development, and independent innovation, Beijing Haijing Gaochuang is capable of undertaking various non-standard customized projects and equipment, including the R&D and production of Class II medical devices. With its foundation in nucleic acid equipment and a broader focus on the general health industry, the company has truly achieved specialized expertise complemented by diverse capabilities.

Qingdao Judianer Technology Co., Ltd. is located in the Blue Biopharmaceutical Industrial Park within the Qingdao High-Tech Industrial Development Zone, Shandong Province. The company is primarily engaged in the research and development and production of DNA/RNA synthesis-related reagents and consumables, as well as series of nucleotide modifiers and nucleoside phosphoramidite monomers. It strictly manages its laboratory environment in accordance with the GB/T 24001-2016/ISO 14001:2015 standard, and rigorously adheres to the GB/T 19001-2016/ISO 9001:2015 standard. Through standardized process guidance, strict implementation, and continuous improvement, the company ensures the consistency and stability of its products.

The products are primarily applicable to the synthesis and purification of nucleic acid compounds, R&D of nucleic acid drugs, chemical biology, gene synthesis and detection, medical diagnostics, and related basic research. Meanwhile, the company has established strong collaborative relationships with numerous renowned domestic pharmaceutical R&D and testing enterprises, universities, and research institutes. It provides customers with customized development of nucleoside and nucleic acid products, along with comprehensive technical services—offering end-to-end solutions from equipment to products and from research to commercialization, thereby facilitating the development of the health industry and advancing life sciences.

Hunan Hengyi Technology Co., Ltd. serves as the core hub for foreign trade sales, primarily responsible for developing and selling equipment, raw materials, and consumables in international markets. The company maintains high-frequency collaborations with key distributors across multiple countries worldwide, playing a vital role in facilitating the global expansion of relevant products and services within the Juhai Hengchuang Group. As the sales platform for Juhai Hengchuang, Hunan Hengyi is committed to providing high-quality products and sales services to the life and health industry.

The three subsidiaries have formed an integrated cycle encompassing R&D, production, and sales, endowing Juhai Hengchuang Group with significant scalability and forward-looking vision.

Over the years, the company has continuously deepened its industry expertise and expanded its market presence, establishing close collaborations with numerous renowned enterprises and universities, including BGI, Peking University, WuXi AppTec, Daan Gene, GenScript Biotech, Tsinghua University, Thermo Fisher Scientific, and HEC Group. Meanwhile, the company has strategically positioned itself for global expansion. Currently, its products are exported to more than 10 countries and regions worldwide, it has established strong connections with over 20 countries, and it has appointed stable and reliable distributors in five countries.

Hangzhou Juhai Hengchuang Technology Co., Ltd. remains steadfast in its commitment to prioritizing customer service, ensuring survival through quality, and guaranteeing reliability through attention to detail, while continuously optimizing product performance and refining manufacturing processes.

Over the past few years since its inception, Hangzhou Juhai Hengchuang Technology Co., Ltd. has adhered to its mission of grounding itself in practical applications and pursuing excellence in quality. The company has successfully obtained more than 30 intellectual property rights, including utility model patents for products such as vacuum filtration devices, liquid delivery systems, and fully automated nucleic acid elution and purification workstations; computer software copyright registrations for control software such as Single-Channel Pump Synthesizer Control Software (V1.0) and Multi-Channel Automated Synthesizer Control Software; and invention patents covering thio-phosphoramidites, their preparation methods, and applications thereof.

This not only reflects the company’s relentless pursuit of innovative technologies and its rigorous control over quality and details, but also demonstrates its widely recognized capabilities.

TigerYeah Capital, established in 2014, is a controlled subsidiary of Tigermed and one of its core investment platforms. Currently, TigerYeah manages six RMB-denominated funds, with assets under management exceeding RMB 2 billion. The core team at TigerYeah consists of graduates from top-tier universities both in China and abroad, boasting profound industry expertise, extensive sector resources, and rich investment experience. With outstanding investment performance, the firm has gained widespread recognition from portfolio companies, limited partners, and the broader community.

Deshi Capital is a specialized private equity investment management firm focused on investments in the pharmaceutical and healthcare sectors. Deshi Capital is committed to identifying investment opportunities in niche markets, collaborating with entrepreneurs and founders to drive transformation in the pharmaceutical and healthcare industries.